Business Context and Reporting Period
This Form 8-K Current Report was filed by Cerecor Inc. on April 11, 2016. The filing discloses a material event regarding a research and development grant award received from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the grant award amount.
- Grant Award: Approximately $1.0 million from NIDA.
- Use of Funds: Resources allocated to the ongoing Phase 2 clinical trial for CERC-501.
Material Changes
The material change reported is the receipt of the $1.0 million grant. This funding supports the "A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior." No comparative financial data or changes versus prior periods are provided in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the grant and its application to the CERC-501 Phase 2 trial. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the standard regulatory disclosures associated with the grant. The information is furnished under Regulation FD and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific terms and milestones associated with the $1.0 million NIDA grant.
- Review the attached press release (Exhibit 99.1) for details on the CERC-501 clinical trial design.
- Check subsequent filings for the impact of this grant on the company's cash runway and operational timeline.
- Confirm the current status of the Phase 2 clinical trial for CERC-501.